Management of bullous pemphigoid: Recommendations for immunomodulatory treatments

American Journal of Clinical Dermatology

Volumn 5, Issue 5, 2004, Pages 319-326

  Kirtschig, Gudula ^a   Khumalo, Nonhlanhla P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; IMMUNOMODULATING AGENT; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; PROBENECID; SULFAMETHOXYPYRIDAZINE; SULFAPYRIDINE; SULFONAMIDE; TACROLIMUS; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VITAMIN D;

ALOPECIA; BACTERIAL SKIN DISEASE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CANCER; CARCINOGENESIS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DERMATITIS HERPETIFORMIS; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; EOSINOPHILIA; EYE DISEASE; FLUSHING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEADACHE; HEARTBURN; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERTENSION; IMMUNOMODULATION; LIVER FIBROSIS; LIVER TOXICITY; LYMPHADENOPATHY; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OBESITY; PATHOGENESIS; PEMPHIGOID; PEPTIC ULCER; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; TACHYCARDIA; TERATOGENESIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRAL SKIN DISEASE;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; NIACINAMIDE; PEMPHIGOID, BULLOUS; PLASMA EXCHANGE;

EID: 10644287489     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405050-00005     Document Type: Review

References (41)

1. Khumalo NP, Kirtschig G, Middleton P, et al. Interventions for bullous pemphigoid (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Oxford Update Software, 2003
2. Lever WF. Pemphigus. Medicine 1953; 32: 1-123
3. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 1993; 120: 518-21
4. Burton JL, Harman RR, Peachey RD, et al. Azathioprine plus prednisone in treatment of pemphigoid. BMJ 1978; 2: 1190-1
5. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day: a multicenter randomized study. Ann Dermatol Venereol 1984; 111: 925-8
6. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 11: 486-8
7. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53
8. Fivenson D, Breneman D, Rosen G, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8
9. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7
10. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989; 20: 458-61
11. Zimmermann R, Faure M, Claudy A. Étude prospective du traitment de la pemphigoide par un dermatocorticoide classe I. Ann Dermatol Venereol 1999; 126: 13-6
12. Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroids. Pediatr Dermatol 1996; 13: 239-45
13. Carruthers JA, August PJ, Stoughton R. Observations of topical clobetasol propionate. BMJ 1979; 4: 203-4
14. Wojnarowska F, Kirtschig G, Highet A, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21
15. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957-60
16. Beissert S, Frieling U, Luger TA. Results of a multicentre, randomised clinical study to compare azathioprine versus mycophenolate mofetil for the treatment of acquired bullous autoimmune disease [abstract]. J Eur Acad Dermatol Venereol 2002; 16 Suppl. 1: 36
17. Appelhans M, Bonsmann G, Örge C, et al. Dexamethasone- cyclophosphamide pulse therapy in bullous autoimmune dermatoses [in German]. Hautarzt 1993; 44: 143-7
18. Taieb A, Klene C, Maleville J. Immediate treatment of bullous pemphigoid with a corticosteroid-cyclophosphamide combination [in French]. Ann Dermatol Venereol 1986; 113: 1223-9
19. Heilbom JD, Stahle-Baeckdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741-9
20. Dereure O, Bessis D, Guillot B, et al. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002; 138: 1255-6
21. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 144: 100-3
22. Barthelemy H, Thivolet J, Cambazard F, et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol 1986; 113: 309-13
23. Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003; 139: 813-5
24. Lebeau S, Mainetti S, Masouye C, et al. Localized childhood vulval pemphigoid with tacrolimus ointment. Dermatology 2004; 208: 273-5
25. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22: 796-801
26. Bouscarat F, Choisdow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683-4
27. Jeffes EW, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989; 14: 132-6
28. Humbert P, Treffel P, Chapuis JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-7
29. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 2001; 26: 376-9
30. Schmidt E, Obe K, Bröcker EB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-8
31. Altomare G, Capella GL, Fracchiolla C, et al. Treatment of bullous pemphigoid with erythromycin: a reappraisal. Eur J Dermatol 1999; 9: 583-5
32. Honl BA, Elston DM. Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide. Cutis 1998; 62: 85-6
33. Thomson Micromedex. Niacinamide, 2003; 118
34. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-35
35. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26: 127-31
36. Ruetter A, Luger T. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44: 1010-24
37. Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol 2002; 29: 781-5
38. Farrell AM, Kirtschig G, Dalziel KL, et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol 1999; 140: 308-12
39. Oranje A, Vuzevski VD, van Joost T, et al. Bullous pemphigoid in children. Int J Dermatol 1991; 30: 339-42
40. Nyul Z, Harangi F, Varszegi D, et al. Vesicobullous lesions in a child. Arch Dermatol 1997; 133: 775-6
41. Fisler RE, Saeb M, Liand MG, et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol 2003; 25: 183-9